RDA Financial Network’s Vertex Pharmaceuticals VRTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$3.39M Sell
6,477
-1,942
-23% -$994K 0.74% 34
2026
Q2
$4.18M Buy
8,419
+1,236
+17% +$548K 0.91% 27
2026
Q1
$3.21M Buy
7,183
+344
+5% +$160K 0.8% 26
2025
Q4
$3.1M Buy
6,839
+130
+2% +$56K 0.75% 29
2025
Q3
$2.63M Buy
6,709
+1,858
+38% +$776K 0.65% 33
2025
Q2
$2.16M Sell
4,851
-207
-4% -$95.4K 0.58% 43
2025
Q1
$2.45M Buy
5,058
+41
+0.8% +$19.1K 0.73% 35
2024
Q4
$2.02M Sell
5,017
-2,375
-32% -$1.1M 0.59% 48
2024
Q3
$3.44M Buy
7,392
+523
+8% +$251K 1.07% 21
2024
Q2
$3.22M Buy
6,869
+4,587
+201% +$1.99M 1.05% 22
2024
Q1
$954K Buy
2,282
+569
+33% +$241K 0.33% 88
2023
Q4
$697K Buy
1,713
+338
+25% +$125K 0.26% 94
2023
Q3
$478K Buy
1,375
+336
+32% +$118K 0.21% 112
2023
Q2
$366K Buy
1,039
+170
+20% +$57.3K 0.15% 140
2023
Q1
$274K Buy
+869
New +$261K 0.12% 171

Other funds holding VRTX

RDA Financial Network's VRTX Position: Q3 2026 in Review

RDA Financial Network reduced its Vertex Pharmaceuticals (VRTX) stake by 23% in Q3 2026, selling an estimated $994K and leaving 6,477 shares worth $3.39M. The position accounts for 0.74% of the portfolio, ranked #34.

RDA Financial Network first reported a position in VRTX in Q1 2023 and has held it in 15 quarters since. The position peaked at $4.18M in Q2 2026. 478 funds tracked by Wall St. Rank hold VRTX as of Q3 2026.

  • RDA Financial Network held 6,477 shares of Vertex Pharmaceuticals worth $3.39M as of Q3 2026.
  • RDA Financial Network sold 1,942 Vertex Pharmaceuticals shares in Q3 2026, an estimated $994K.
  • Vertex Pharmaceuticals made up 0.74% of RDA Financial Network's portfolio in Q3 2026, its #34 holding.
  • RDA Financial Network first reported a position in Vertex Pharmaceuticals in Q1 2023 and has held it in 15 quarters since.
  • RDA Financial Network's Vertex Pharmaceuticals position peaked at $4.18M in Q2 2026.
  • 478 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2026.

Based on RDA Financial Network's 13F filing for Q3 2026, filed 15 Oct 2026.